Carbapenemase VCC-1 from Vibrio cholerae N14-02106Carbapenemase VCC-1 from Vibrio cholerae N14-02106

Structural highlights

6mk6 is a 4 chain structure with sequence from Vibrio cholerae. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 1.7Å
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

A0A0U3IB62_VIBCL

Publication Abstract from PubMed

In 2016 we identified a new class A carbapenemase, VCC-1, in nontoxigenic Vibrio cholerae that had been isolated from retail shrimp imported into Canada for human consumption. Shortly thereafter, seven additional VCC-1 producing V. cholerae were isolated along the German coastline. These isolates appear to have acquired the VCC-1 gene (bla VCC-1) independently from the Canadian isolate, suggesting bla VCC-1 is mobile and widely distributed. VCC-1 hydrolyzes penicillins, cephalothin, aztreonam, and carbapenems, and like the broadly disseminated class A carbapenemase KPC-2, is only weakly inhibited by clavulanic acid or tazobactam. Although VCC-1 has yet to observed in the clinic, its encroachment into aquaculture and other areas with human activity suggests the enzyme may be emerging as a public health threat. To pre-emptively address this threat, we examined the structural and functional biology of VCC-1 against the FDA approved non-beta-lactam-based inhibitor avibactam. We found that avibactam restored the in vitro sensitivity of V. cholerae to meropenem, impenem and ertapenem. Acylation efficiency was lower for VCC-1 as compared to KPC-2 and akin to that of Pseudomonas aeruginosa PAO1 AmpC (k2/Ki=3.0 x 10(3) M(-1)sec(-137)). The tertiary structure of VCC-1 is similar to that of KPC-2 and they bind avibactam similarly; however, our analyses suggest that VCC-1 may be unable to degrade avibactam as has been found for KPC-2. Based on our prior genomics-based surveillance, we were able to target VCC-1 for detailed molecular studies to gain early insights that could be used to combat this carbapenemse in the future.

Molecular basis for the potent inhibition of the emerging carbapenemase VCC-1 by avibactam.,Mangat CS, Vadlamani G, Holicek V, Chu M, Larmour V, Vocadlo DJ, Mulvey MR, Mark BL Antimicrob Agents Chemother. 2019 Feb 19. pii: AAC.02112-18. doi:, 10.1128/AAC.02112-18. PMID:30782990[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Mangat CS, Vadlamani G, Holicek V, Chu M, Larmour V, Vocadlo DJ, Mulvey MR, Mark BL. Molecular basis for the potent inhibition of the emerging carbapenemase VCC-1 by avibactam. Antimicrob Agents Chemother. 2019 Feb 19. pii: AAC.02112-18. doi:, 10.1128/AAC.02112-18. PMID:30782990 doi:http://dx.doi.org/10.1128/AAC.02112-18

6mk6, resolution 1.70Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA